标题
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-11-14
DOI
10.1186/s40425-019-0784-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program
- (2019) Shenda Hou et al. JOURNAL OF EXPERIMENTAL MEDICINE
- EZH2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis
- (2019) Yu Zhao et al. EMBO JOURNAL
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- Glycolytic Activation of Peritumoral Monocytes Fosters Immune Privilege via PFKFB3-PD-L1 axis in Human Hepatocellular Carcinoma
- (2019) Dong-Ping Chen et al. JOURNAL OF HEPATOLOGY
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
- (2019) Yuan Wei et al. JOURNAL OF CLINICAL INVESTIGATION
- Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
- (2018) Chao-Qun Liu et al. BRITISH JOURNAL OF CANCER
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Novel targeted therapies and immunotherapy for advanced thyroid cancers
- (2018) George E. Naoum et al. Molecular Cancer
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
- (2018) Alison Hirukawa et al. Nature Communications
- Regulation of Breast Cancer-Induced Osteoclastogenesis by MacroH2A1.2 Involving EZH2-Mediated H3K27me3
- (2018) Jinman Kim et al. Cell Reports
- PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
- (2018) A. Asgarova et al. OncoImmunology
- The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
- (2018) Helen Loo Yau et al. TRENDS IN CELL BIOLOGY
- A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas
- (2018) Gouji Toyokawa et al. ANNALS OF THORACIC SURGERY
- Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy
- (2017) Jingying Zhou et al. GUT
- Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma
- (2017) Thai Huu Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
- (2017) Xun Jin et al. NATURE MEDICINE
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
- (2017) Faizaan Mohammad et al. NATURE MEDICINE
- IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
- (2017) Ji Wook Moon et al. Scientific Reports
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
- (2016) Karen Weintraub NATURE MEDICINE
- PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
- (2015) Nisha Nagarsheth et al. CANCER RESEARCH
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
- (2014) Zhen Ning Wee et al. Cell Reports
- Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming
- (2013) Neha Tiwari et al. CANCER CELL
- Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin
- (2013) Chi Han Li et al. GASTROENTEROLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
- (2011) J. Zhou et al. BLOOD
- EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
- (2011) M.-Y. Cai et al. GUT
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
- (2011) Francesco Crea et al. Molecular Cancer
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells
- (2009) Dong-Ming Kuang et al. HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started